Lilly Antibody Proves Ineffective In Rheumatoid Arthritis, But Lupus Trials Continue
This article was originally published in The Pink Sheet Daily
Lilly has stopped one Phase III rheumatoid arthritis trial for its anti-BAFF antibody tabalumab and ceased enrollment in two others after a mid-term analysis revealed a lack of efficacy, but the company is soldiering on with a Phase III program in lupus erythematosus.
You may also be interested in...
Alzheimer’s disease research could be a beneficiary of Europe’s plan to include more non-EU partners in its new science funding program, Horizon 2020, and a new version of its public-private partnership with the pharmaceutical industry, the Innovative Medicines Initiative.
A group of CEOs from Big Pharma, biotech and finance companies have joined forces with philanthropists and health care policy makers to call for a global action plan against Alzheimer's disease.
The company terminates all late-stage development of the anti-B cell antibody in rheumatoid arthritis due to lack of efficacy. Ongoing studies in lupus and multiple myeloma are expected to begin reporting in 2014.